Sign inJoin waitlistJoin the waitlist

AS

Aixa Soyano

Assistant Professor, Department of Medical Oncology · H. Lee Moffitt Cancer Center

Credentials: · · · · · ·

History

H. Lee Moffitt Cancer Center
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2015–2018
Internal Medicine
Boston Medical Center-Brighton
2012–2015
Doctor of Medicine
2004–2008

Research

Next generation of immune checkpoint therapy in cancer: new developments and challenges
Review · Journal of Hematology & Oncology · 2018 · 630 citations
Cancer immunotherapy beyond immune checkpoint inhibitors
Review · Journal of Hematology & Oncology · 2018 · 154 citations
Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
Journal for ImmunoTherapy of Cancer · 2018 · First of 11 authors · 109 citations

HS
Hatem Soliman
18 papers
Brian Czerniecki
16 papers
HH
Hyo Han
16 papers
RC
Ricardo Costa
12 papers
AA
Avan Armaghani
11 papers
PF
Peter Forsyth
9 papers
Kamran Ahmed
8 papers
LL
Loretta Loftus
8 papers
ML
Marie Lee
7 papers
Bhagirathbhai Dholaria
6 papers · 5 as a fellow
HY
Hsiang-Hsuan Yu
6 papers
MM
Matthew Mills
6 papers · 4 as a resident

Clinical trials

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
Principal investigator · Recruiting · Phase 2
H. Lee Moffitt Cancer Center and Research Institute
2024–2027
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Eli Lilly and Company
2023–2030
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2021–2026